We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+57.51%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$3.59B
AUM Growth
+$852M
Cap. Flow
-$15.9M
Cap. Flow %
-0.44%
Top 10 Hldgs %
60.96%
Holding
76
New
4
Increased
9
Reduced
2
Closed
9

Top Buys

Rank Stock Value
1
IDYA icon
IDEAYA Biosciences
IDYA
+$66.4M
2
JANX icon
Janux Therapeutics
JANX
+$33.7M
3
RVMD icon
Revolution Medicines
RVMD
+$31.9M
4
PVLA
Palvella Therapeutics
PVLA
+$11.8M
5
ALLK
Allakos
ALLK
+$11.7M

Top Sells

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$45.3M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$44M
3
IMVT icon
Immunovant
IMVT
+$39.7M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$37M
5
MRUS
Merus
MRUS
+$30.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTIC
76
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-8,813,021
Closed -$37M
1 2 3
4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2023 Portfolio in Review

As of Q2 2023, BVF Inc held 76 positions worth $3.59B, up 31% from $2.74B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

BVF Inc's Q2 2023 filing shows 4 new, 9 increased, 2 reduced and 9 closed positions. Its largest new stake was TScan Therapeutics: 2,989,474 shares worth $7.47M. The largest sale was Syndax Pharmaceuticals, an estimated $45.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • BVF Inc's largest Q2 2023 buy was TScan Therapeutics: 2,989,474 shares worth $7.47M.
  • BVF Inc added most to IDEAYA Biosciences in Q2 2023, an estimated $66.4M increase.
  • BVF Inc's biggest Q2 2023 reduction was Merus, cutting an estimated $30.1M.
  • BVF Inc fully exited Syndax Pharmaceuticals in Q2 2023, selling an estimated $45.3M.
  • BVF Inc's ten largest holdings make up 61% of its $3.59B portfolio in Q2 2023.
  • BVF Inc opened 4 new positions and closed 9 in Q2 2023.
  • BVF Inc's portfolio value rose 31% quarter-over-quarter to $3.59B.

Based on BVF Inc's 13F filing for Q2 2023, filed 14 Aug 2023.